Frontlight ResearchEarly access
TerminatedPhase 1
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 2 people enrolled
- Started
- 16 Jul 2024
- Ended
- 4 Dec 2024
- Type of study
- Interventional
- Treatments tested
- Naltrexone (Vivitrol)
- Bupropion
- Record updated
- 16 September 2025
- Why it stopped
- Unable to recruit eligible participants and expiration of study medication.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- fluent in English
- Diagnosed with schizophrenia spectrum disorder that is currently stable
- Report regular cigarette smoking, average cigarette per day ≥ 5 in the past 4 weeks, and present a breath CO≥10 ppm
- Meet subjective and objective (urinary drug screen) measures of non-opioid use
- If female, present a negative pregnancy test, not be currently breast feeding, and agree to use acceptable birth control methods and receive periodic pregnancy tests during the course of the study
- Able to give written informed consent
- Obtain an Evaluation to Sign Consent (ESC) score above 10
Who cannot take part
- Previous use of bupropion or naltrexone in the past 30 days
- Be medically unstable or taking medications that are contraindicated with using naltrexone or bupropion
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5 )criteria for alcohol and other substance use disorders excluding nicotine and marijuana
- Report a history of epilepsy, seizure disorder or condition increasing risk of seizure, or head trauma with neurological sequelae
- Have a current eating disorder
- Have suicidal or homicidal ideation requiring immediate attention
- Currently enrolled in treatment for tobacco use
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United States
About the trial
What the trial wants to find out
The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.
The group in the trial
- TreatmentTreatment being tested
Treatment: Naltrexone (Vivitrol) and Bupropion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-label Pilot Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
- Record updated
- 16 September 2025